Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer

2013 ◽  
Vol 31 (4) ◽  
pp. 468-474 ◽  
Author(s):  
Goran Benko ◽  
Borislav Spajić ◽  
Božo Krušlin ◽  
Davor Tomas
2001 ◽  
Vol 166 (2) ◽  
pp. 416-419 ◽  
Author(s):  
MISOP HAN ◽  
ALAN W. PARTIN ◽  
STEVEN PIANTADOSI ◽  
JONATHAN I. EPSTEIN ◽  
PATRICK C. WALSH

Author(s):  
Fumihiko Urabe ◽  
Shoji Kimura ◽  
Shutaro Yamamoto ◽  
Kojiro Tashiro ◽  
Takahiro Kimura ◽  
...  

Abstract Background The influence of family history on oncological outcomes of prostate cancer remains controversial. We conducted a systematic literature review and meta-analysis to investigate the impact of family history of localized prostate cancer on oncological outcomes. Methods On May 2020, we systematically searched MEDLINE, the Cochrane library, and Scopus for studies that compared patients who had localized prostate cancer with or without a positive family history of prostate cancer. Our aim was to evaluate the association of family history with biochemical recurrence-free survival, cancer-specific survival, and overall survival by means of a multivariate Cox regression analysis. Results Eleven studies with 39,716 patients were included in the systematic review, and eight studies with 33,027 patients for the meta-analysis. A positive family history was not associated with worse biochemical recurrence-free survival (pooled HR: 0.96; 95% CI: 0.79–1.17) or cancer-specific survival (pooled HR: 1.1; 95% CI: 0.52–2.35). Subgroup analyses showed no association between positive family history and poor biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy (pooled HR: 0.99; 95% CI: 0.76–1.31) or radiation therapy (pooled HR: 0.93; 95% CI: 0.67–1.30). Conclusions This meta-analysis indicated that family history of prostate cancer does not increase the risk of biochemical recurrence or cancer-specific mortality in localized prostate cancer patients.


2019 ◽  
Vol 76 (9) ◽  
pp. 929-934
Author(s):  
Jovo Bogdanovic ◽  
Vuk Sekulic ◽  
Sandra Trivunic-Dajko ◽  
Ranko Herin ◽  
Senjin Djozic

Background/Aim. Pelvic lymph node dissection (PLND) is the most accurate staging procedure in the diagnosis of lymph node involvement by prostate cancer. However, the therapeutic value of this procedure is still unclear. The objective of the study was to compare diagnostic and therapeutic values of extended and standard PLND as an adjunct of radical prostatectomy. Methods. The patients who underwent surgical treatment for clinically localized prostate cancer (n = 157) were enrolled in this open nonrandomized prospective study. In the standard PLND (sPLND) group 109 patients were enrolled while the extended PLND (ePLND) group involved 48 patients. Both groups were compared regarding age, prostate-specific antigen (PSA) level, a percentage of positive biopsies, preoperative and postoperative Gleason score, number of retrieved and positive lymph nodes, duration of surgery, blood loss, amount of lymphorrhea and biochemical recurrence-free survival. Results. The average number of retrieved lymph nodes was 17.27 and 24.46 in the sPLND and ePLND group, respectively (p = 0.001). The rate of positive lymph nodes was 9/109 (8.3%) and 8/48 (16.7%) in the sPLND and ePLND groups, respectively. Biochemical recurrence was noted in 38/109 (31.2%) and 7/48 (14.6%) patients in the sPLND and ePLND group, respectively (p = 0.003). Conclusion. Comparison of sPLND to ePLND led to the following conclusions: nodal yield was significantly higher in the ePLND group; the ePLND template was associated with a much higher rate of lymph node metastases; the biochemical recurrence-free survival rate was significantly more favorable in the ePLND group comparing to the sPLND group.


2008 ◽  
Vol 14 (3) ◽  
pp. 758-763 ◽  
Author(s):  
Joseph R. Sterbis ◽  
Chunling Gao ◽  
Bungo Furusato ◽  
Yongmei Chen ◽  
Syed Shaheduzzaman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document